AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks  WSJ

The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

AstraZeneca shares tumble 7% after reported Bristol Myers talks  Reuters

AstraZeneca shares fall on Bristol Myers Squibb merger talks  The Times

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.